Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Baxter
Mallinckrodt
McKinsey
Medtronic

Last Updated: January 28, 2023

Hoffmann La Roche Company Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Hoffmann La Roche
International Patents:277
US Patents:11
Tradenames:11
Ingredients:10
NDAs:13

Drugs and US Patents for Hoffmann La Roche

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann La Roche ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER ceftriaxone sodium INJECTABLE;INJECTION 050624-003 Feb 11, 1987 DISCN Yes No See Plans and Pricing See Plans and Pricing
Hoffmann La Roche INVIRASE saquinavir mesylate CAPSULE;ORAL 020628-001 Dec 6, 1995 DISCN Yes No See Plans and Pricing See Plans and Pricing
Hoffmann La Roche BONIVA ibandronate sodium TABLET;ORAL 021455-002 Mar 24, 2005 DISCN Yes No 7,410,957 See Plans and Pricing See Plans and Pricing
Hoffmann La Roche ZELBORAF vemurafenib TABLET;ORAL 202429-001 Aug 17, 2011 RX Yes Yes 7,504,509 See Plans and Pricing Y Y See Plans and Pricing
Hoffmann La Roche ZELBORAF vemurafenib TABLET;ORAL 202429-001 Aug 17, 2011 RX Yes Yes 9,447,089 See Plans and Pricing Y See Plans and Pricing
Hoffmann La Roche ZELBORAF vemurafenib TABLET;ORAL 202429-001 Aug 17, 2011 RX Yes Yes See Plans and Pricing See Plans and Pricing
Hoffmann La Roche ACCUTANE isotretinoin CAPSULE;ORAL 018662-003 May 7, 1982 DISCN Yes No See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Hoffmann La Roche

Paragraph IV (Patent) Challenges for HOFFMANN LA ROCHE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe For Oral Solution 50 mg/mL ➤ Subscribe 2011-03-21
➤ Subscribe Tablets 2.5 mg and 150 mg ➤ Subscribe 2007-05-16
➤ Subscribe Tablets 450 mg ➤ Subscribe 2005-12-27
➤ Subscribe Injection 1 mg/mL, 3 mL Vial ➤ Subscribe 2007-08-31
➤ Subscribe Tablets 150 mg and 500 mg ➤ Subscribe 2008-11-10
Premature patent expirations for HOFFMANN LA ROCHE

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
See Plans and Pricing See Plans and Pricing

International Patents for Hoffmann La Roche Drugs

Country Patent Number Estimated Expiration
Mexico 2012001463 See Plans and Pricing
European Patent Office 3088400 See Plans and Pricing
Norway 20076659 See Plans and Pricing
Cyprus 1116233 See Plans and Pricing
Poland 1696920 See Plans and Pricing
South Korea 20130128488 See Plans and Pricing
European Patent Office 2395004 See Plans and Pricing
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for Hoffmann La Roche Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0694547 SPC/GB02/027 United Kingdom See Plans and Pricing PRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425
0316704 2001C/021 Belgium See Plans and Pricing PRODUCT NAME: CAPECITABINE, NATL REGISTRATION NO/DATE: EU/1/00/163/001 20010205; FIRST REGISTRATION: CH 54657 19980610
1893612 132012902073472 Italy See Plans and Pricing PRODUCT NAME: VEMURAFENIB(ZELBORAF); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/12/751/001, 20120221
0316704 SPC/GB01/015 United Kingdom See Plans and Pricing PRODUCT NAME: CAPECITABINE AND HYDRATES AND SOLVATES THEREOF; REGISTERED: CH 54657 19980610; UK EU/1/00/163/001-002 20010202
1893612 2012C/028 Belgium See Plans and Pricing PRODUCT NAME: VERMURAFENIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, SOUS TOUTES FORMES COUVERTES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/12/751/001 20120221
1893612 C20120016 00059 Estonia See Plans and Pricing PRODUCT NAME: ZELBORAF - VEMURAFENIIB;REG NO/DATE: C(2012)1180 FINAL 17.02.2012
1893612 28/2012 Austria See Plans and Pricing PRODUCT NAME: VEMURAFENIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/12/751/001 (MITTEILUNG) 20120221
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
AstraZeneca
McKesson
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.